Literature DB >> 32887531

Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform.

Lukas Pekar1, Michael Busch2, Bernhard Valldorf3, Steffen C Hinz1, Lars Toleikis4, Simon Krah4, Stefan Zielonka4.   

Abstract

Here, we report the characterization of a VHH-derived IgG-like bi- and trispecific antibody platform that essentially relies on the replacement of the VH and VL regions of a conventional antibody by two independently functioning VHH domains. Consequently, a VHH is engrafted onto constant region CH1 while the other VHH-based paratope is engrafted on the constant region of the light chain, Cκ or Cλ, resulting in a tetravalent bispecific IgG-like molecule. Combined with a heavy chain heterodimerization technique, this platform allows facile engineering of bi- and trispecific antibodies with flexible valencies. We demonstrate the general applicability of this generic platform approach and elaborate on the limitations of specific formats.

Entities:  

Keywords:  Antibody engineering; IgG-like; VHH; bispecific antibody; camelid; nanobody; single-domain antibody; trispecific antibody

Year:  2020        PMID: 32887531      PMCID: PMC7531565          DOI: 10.1080/19420862.2020.1812210

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  31 in total

1.  Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design.

Authors:  Enrico L Digiammarino; John E Harlan; Karl A Walter; Uri S Ladror; Rohinton P Edalji; Charles W Hutchins; Marc R Lake; Amy J Greischar; Junjian Liu; Tariq Ghayur; Clarissa G Jakob
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

2.  Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab.

Authors:  Giovanna Scapin; Xiaoyu Yang; Winifred W Prosise; Mark McCoy; Paul Reichert; Jennifer M Johnston; Ramesh S Kashi; Corey Strickland
Journal:  Nat Struct Mol Biol       Date:  2015-11-23       Impact factor: 15.369

Review 3.  Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.

Authors:  Alessandro Satta; Delia Mezzanzanica; Fabio Turatti; Silvana Canevari; Mariangela Figini
Journal:  Future Oncol       Date:  2013-04       Impact factor: 3.404

4.  Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.

Authors:  Caroline Rozan; Amélie Cornillon; Corinne Pétiard; Martine Chartier; Ghislaine Behar; Charlotte Boix; Brigitte Kerfelec; Bruno Robert; André Pèlegrin; Patrick Chames; Jean-Luc Teillaud; Daniel Baty
Journal:  Mol Cancer Ther       Date:  2013-06-11       Impact factor: 6.261

5.  Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

Authors:  Chengbin Wu; Hua Ying; Christine Grinnell; Shaughn Bryant; Renee Miller; Anca Clabbers; Sahana Bose; Donna McCarthy; Rong-Rong Zhu; Ling Santora; Rachel Davis-Taber; Yune Kunes; Emma Fung; Annette Schwartz; Paul Sakorafas; Jijie Gu; Edit Tarcsa; Anwar Murtaza; Tariq Ghayur
Journal:  Nat Biotechnol       Date:  2007-10-14       Impact factor: 54.908

6.  Isolation of Antigen-Specific VHH Single-Domain Antibodies by Combining Animal Immunization with Yeast Surface Display.

Authors:  Lukas Roth; Simon Krah; Janina Klemm; Ralf Günther; Lars Toleikis; Michael Busch; Stefan Becker; Stefan Zielonka
Journal:  Methods Mol Biol       Date:  2020

7.  Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity.

Authors:  Andrew D Tustian; Christine Endicott; Benjamin Adams; John Mattila; Hanne Bak
Journal:  MAbs       Date:  2016-03-10       Impact factor: 5.857

8.  Antibodies to watch in 2019.

Authors:  Hélène Kaplon; Janice M Reichert
Journal:  MAbs       Date:  2018-12-22       Impact factor: 5.857

Review 9.  Antibodies to watch in 2020.

Authors:  Hélène Kaplon; Mrinalini Muralidharan; Zita Schneider; Janice M Reichert
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

10.  TriFabs--Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery.

Authors:  Klaus Mayer; Anna-Lena Baumann; Michael Grote; Stefan Seeber; Hubert Kettenberger; Sebastian Breuer; Tobias Killian; Wolfgang Schäfer; Ulrich Brinkmann
Journal:  Int J Mol Sci       Date:  2015-11-17       Impact factor: 5.923

View more
  7 in total

1.  Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity.

Authors:  Adrian Elter; Desislava Yanakieva; David Fiebig; Kerstin Hallstein; Stefan Becker; Ulrich Betz; Harald Kolmar
Journal:  Front Immunol       Date:  2021-08-03       Impact factor: 7.561

2.  Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection.

Authors:  Daniel Klewinghaus; Lukas Pekar; Paul Arras; Simon Krah; Bernhard Valldorf; Harald Kolmar; Stefan Zielonka
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

3.  Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities.

Authors:  Desislava Yanakieva; Lukas Pekar; Andreas Evers; Markus Fleischer; Stephan Keller; Dirk Mueller-Pompalla; Lars Toleikis; Harald Kolmar; Stefan Zielonka; Simon Krah
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

4.  Milking the Cow: Cattle-Derived Chimeric Ultralong CDR-H3 Antibodies and Their Engineered CDR-H3-Only Knobbody Counterparts Targeting Epidermal Growth Factor Receptor Elicit Potent NK Cell-Mediated Cytotoxicity.

Authors:  Lukas Pekar; Daniel Klewinghaus; Paul Arras; Stefania C Carrara; Julia Harwardt; Simon Krah; Desislava Yanakieva; Lars Toleikis; Vaughn V Smider; Harald Kolmar; Stefan Zielonka
Journal:  Front Immunol       Date:  2021-10-25       Impact factor: 7.561

5.  Quantification of natural abundance NMR data differentiates the solution behavior of monoclonal antibodies and their fragments.

Authors:  David Ban; Cory T Rice; Mark A McCoy
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

6.  Anticalin N- or C-Terminal on a Monoclonal Antibody Affects Both Production and In Vitro Functionality.

Authors:  Nicolas Aubrey; Valérie Gouilleux-Gruart; Christine Dhommée; Julie Mariot; Fanny Boursin; Nicolas Albrecht; Cécile Bergua; Cécile Croix; Mäelle Gilotin; Eloi Haudebourg; Catherine Horiot; Laetitia Matthias; Caroline Mouline; Laurie Lajoie; Audrey Munos; Gilles Ferry; Marie-Claude Viaud-Massuard; Gilles Thibault; Florence Velge-Roussel
Journal:  Antibodies (Basel)       Date:  2022-08-22

Review 7.  Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer.

Authors:  Mariam Elshiaty; Hannah Schindler; Petros Christopoulos
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.